STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in leaving the study early: Any reasons ‐ when compared with ultra low… compared with ANY DOSE ‐ short term (moderate certainty).
STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in leaving the study early: Any reasons ‐ when compared with… compared with ANY DOSE ‐ short term (moderate certainty).
STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in leaving the study early: Any reasons ‐ When compared with high dose… compared with ANY DOSE ‐ short term (moderate certainty).
STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in global state: No clinically important improvement ‐ global… compared with ANY DOSE ‐ short term (moderate certainty).
STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in mental state: No clinically important improvement ‐ PANSS ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).
STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) probably leads to higher adverse effects: 6. Movement disorders ‐ specific symptoms ‐… compared with ANY DOSE ‐ short term (moderate certainty).
STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) probably leads to higher adverse effects: 6. Movement disorders ‐ specific symptoms ‐ EPS:… compared with ANY DOSE ‐ short term (moderate certainty).
STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) probably leads to higher adverse effects: 6. Movement disorders ‐ specific symptoms ‐ tremor… compared with ANY DOSE ‐ short term (moderate certainty).